Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp V.SVA


Primary Symbol: T.SVA Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by Sonny7on Aug 19, 2020 2:45pm
153 Views
Post# 31429961

RE:RE:RE:RE:RE:clinical trial dates

RE:RE:RE:RE:RE:clinical trial dateswoundedknee that could be a very real and logical scenario but for the selphie factor that has leeched onto the company. At the risk of sounding like a parrot, I’ll say it again. Matthews is the one single factor responsible for Sernova showing an embarrassingly weak share price in spite of their pristine showings as they advance and prove up their science and technologies. 

I believe that Matthews was hired around the time of the U of A trial that involved weasel shapiro. Weasel shapiro more or less, mostly more, sabotaged that trial, Sernova hired two-bit Matthews to answer the phone for the good doctor to insulate him from all the phone inquiries from shareholders and gave him the IR title. Sernova had no staff and nothing going on but lab studies at the time after the shapiro/U of A fiasco. Matthews apparently lucked out on some deal that became a success and he showed up here with his light experience, inflated ego and a natural talent for being a liar. 

Life went on. Doctor stayed in the lab working on company business and rae selphie Matthews had a runaway on flappin his face, embellishing facts in a free range environment and further inflating his ego. In the beginning I’ll say he did some good in terms of elevating the share price and the doctor was appreciative for the freedom allowed by not being harassed with shareholder phone inquiries. All the while, doctor was able to show progress and prove up the cell pouch idea. 

Soon the pre clinical results, showing promise after the weasel shapiro shitshow, kicked in and Sernova was now invited to high level conferences as presenters and Matthews attended with his ego and childishness rampant in pandemic like proportions. He was like the organ grinders monkey at these conferences with his childish behaviour on full display. With his introduction to the conferences and foreign dignitaries from Worldwide pharmaceutical companies his ignorance and halfwit actions earned him the name change to selphie. There he was firing off cellphone pictures of his life within Sernova, including ones of his ugly mug with a shapiro like smirk on his femme face and two foreign suits behind him in the background in a limousine it looked like. The suits showed  shocked expressions as if to say “Who the F*** is this guy”. A long ways from being astute, that Matthews. Sophisticated and professional not in his vocabulary. 

Needless ro say, with the presentations and subsequent visits with large pharmaceutical companies on Sernova business, the company grew with that kind of exposure from the presentations. Matthews did Not, but for his ego. Nor was Matthews in a learning frame of mind. He couldn’t grow as the company did. He only had his skills as a liar to fall back on and the halfwit apparently liked the idea of name dropping. He hired “designer” or “boutique” IR firms for big dollars, thinking that people would see that and storm the market to buy Sernova’s stock. What can any IR firm do with a company when all they had was a piece of plastic and an idea? NOTHING, but take Sernova’s money. That was the good part. It got worse from there. Matthews was going to make his overpaid job last. 

This was all over a period of about five years and now we get into territory that newer shareholders may have seen. Matthews now was basking in his self created glory with some title to Business Development within the company. You might say that he showed some success at that. He was able to fill out expense account reports. 

Why are are we at this level in terms of share price? Why are Worldwide pharmaceutical companies and medical device companies on the edge of their chairs watching Sernova?  We have pristine people and science on the Sernova side and halfwit rae selphie Matthews on the other. 

If no one had seen this or read about it before, here we bloody well go again. In a nutshell. Matthews lied to some folks that took his word in good faith. They took multi million share positions and their buying propelled the stock to peak at $0.51. Matthews took that and betrayed everyone with a $0.25 financing. A sign of weakness at that price. The betrayal stuck with him and the next financing was worse. His next financing was worse at $0.20, going backward and he sabotaged historical company news to do it. It’s said that he personally capitalized on these financings for personal gain as he betrayed all others as he himself and his sleazy contacts took part in the train wreck. The last financing disaster brought Midam into the picture to contaminate the scene and they and Matthews still fester together in their back alley environment and it’s apparent to some that with Matthews creating this share price weakness, they are fixing to take another run at another go backwards financing scheme in the near future, current share price range being the prime indicator. 
Yup. Matthews and Midam. Same greasy peas in a rotting pod. Sheesh. 

There needs to be a stain remover to get rid of Matthews to refresh the air and get us a look at blue sky. The fear is that as long as he’s around he’ll be blocking that Sernova sunshine. Here’s hoping. 
<< Previous
Bullboard Posts
Next >>